Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
5-day change
1st Jan Change
8.06
USD
+4.40%
+3.47%
-74.36%
This article is reserved for members
Not a member ?
Free registration
North American Morning Briefing : Stock Futures -3-
May. 02
DJ
Sector Update: Health Care Stocks Rise Late Afternoon
May. 01
MT
Sector Update: Health Care
May. 01
MT
Top Midday Decliners
May. 01
MT
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts
May. 01
MT
JPMorgan Downgrades CVRx to Neutral From Overweight, Adjusts Price Target to $13 From $36
May. 01
MT
William Blair Downgrades CVRx to Market Perform From Outperform
May. 01
MT
Investors Await Fed Rate Decision as US Futures Trend Lower in Wednesday's Premarket
May. 01
MT
North American Morning Briefing : Traders Wait for Rate Decision, Powell; AMD Tumbles
May. 01
DJ
Transcript : CVRx, Inc., Q1 2024 Earnings Call, Apr 30, 2024
Apr. 30
Earnings Flash (CVRX) CVRX Reports Q1 Revenue $10.8M, vs. Street Est of $11.4M
Apr. 30
MT
CVRx, Inc. Provides Earnings Guidance for Second Quarter and Full Year of 2024
Apr. 30
CI
CVRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 30
CI
CVRx, Inc. Announces Appointment of Kevin Hykes as President, Effective February 12, 2024
Jan. 31
CI
CVRx, Inc. Announces Chief Executive Officer Changes, Effective February 12, 2024
Jan. 31
CI
JPMorgan Raises CVRx's Price Target to $36 From $31, Keeps Overweight Rating
Jan. 26
MT
CVRx Q4 Net Loss Narrows, Revenue Climbs; Q1, Full-Year 2024 Revenue Guidance Set
Jan. 25
MT
Transcript : CVRx, Inc., Q4 2023 Earnings Call, Jan 25, 2024
Jan. 25
CVRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Jan. 25
CI
Earnings Flash (CVRX) CVRX Posts Q4 Revenue $11.3M, vs. Street Est of $11.1M
Jan. 25
MT
CVRx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Jan. 25
CI
Lake Street Adjusts CVRx Price Target to $35 From $32, Maintains Buy Rating
Jan. 22
MT
Transcript : CVRx, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
Jan. 10
CVRx Shares Drop; CEO to Retire; Preliminary Q4, 2023 Revenue Top Consensus; Q1 Forecast Issued
Jan. 08
MT
CVRx, Inc. Announces Nadim Yared Retires as Chief Executive Officer
Jan. 08
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
More about the company
Last Close Price
8.06
USD
Average target price
16.6
USD
Spread / Average Target
+105.96%
Consensus
1st Jan change
Capi.
-74.36% 174M +73.63% 12.42B -18.62% 7.94B -0.90% 6.17B +14.66% 5.5B +39.93% 5.01B -16.21% 4.88B -16.42% 4.2B -27.62% 2.73B +40.99% 2.27B
Medical Equipment
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**